Saturday, May 2, 2026

China’s EV Exports to North Korea: Are Sanctions Being Violated?

Chinese companies are openly promoting exports to North Korea on Douyin, raising concerns over potential violations of UN sanctions.

North Korea’s 2026 Car Ownership Revolution: What It Means

North Korea's new law allows private car ownership, reflecting economic changes and potential shifts toward a market economy.

North Korea’s 9th Party Congress: Will Ju-ae Solidify the 4th Generation Succession?

Kim Jong Un's succession plans focus on daughter Ju-ae as North Korea prepares for the 9th Workers' Party Congress.

Tag: FDA

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Penetrium Bioscience Announces Finalization of New Clinical Strategy for Targeted Cancer Therapies

Penetrium Bioscience reveals new clinical strategy to combat drug resistance in cancer therapies at AACR 2026, launching Phase 2 trials.

CG Bio’s EasyMade TI: The First Custom Titanium Implant Approved by FDA 510(k) – What It Means for Patients

CG Bio's EasyMade TI titanium implant receives FDA 510(k) approval, marking a milestone for customized implants in the U.S. market.

Lunit supplies integrated breast cancer diagnostic solution to Lexington Clinic

Lunit supplies integrated breast cancer AI solutions to Lexington Clinic, enhancing diagnostics and expanding its presence in the Americas.

How ‘Sunlenkaju’ and ‘Sunlenkajeong’ Are Revolutionizing HIV-1 Therapy in 2026

FDA approves lenacapavir-based HIV treatments for patients with multidrug-resistant infections, enhancing options for difficult cases.

Samchundang Pharma CEO Claims FDA Recognition for Obesity Drug as Generic

Samchundang Pharma's CEO announces FDA recognition of oral semaglutide as a generic and withdraws $1.7 billion stock sale plan.

FDA Grants Orphan Drug Status to Tovecimig: What This Means for Cholangiocarcinoma Treatment

ABL Bio's Tovecimig receives Orphan Drug Designation from the FDA, enhancing its approval prospects for cholangiocarcinoma treatment.

CT-P71: The New ADC Cancer Drug Fast-Tracked by FDA for Urothelial Carcinoma

Celltrion's CT-P71 receives FDA Fast Track designation for urothelial carcinoma, enhancing its ADC pipeline and global drug development efforts.

April 2026: Major Regulatory Actions on Herbal Patches and Antibiotics in South Korea

The FDA suspended manufacturing and sales of several products for regulatory violations, including herbal patches and antibiotic tablets.

Exploring Cenobamate: How SK Biopharmaceuticals’ New Oral Suspension Benefits Adult Epilepsy Patients

SK Biopharmaceuticals submits NDA for Cenobamate oral suspension, enhancing treatment options for epilepsy patients with swallowing difficulties.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

Eli Lilly’s New Weight Loss Pill Foundayo: A Game Changer in the GLP-1 Market?

The FDA has approved Eli Lilly's oral obesity drug Foundayo, enhancing competition in the weight loss market with flexible dosing.

Classys Unveils Aggressive Growth Strategy at AAD 2026: What’s Next for the U.S. Market?

Classys reveals its growth strategy for the U.S. market at AAD 2026, showcasing innovative products and emphasizing clinical efficacy.

HLB’s Liraglutide: A Game-Changer in Cholangiocarcinoma Treatment with FDA Priority Review

HLB's Elevar Therapeutics receives FDA Priority Review for lirafugratinib, a promising treatment for cholangiocarcinoma with a 47% response rate.

FDA’s Game-Changing Guidelines: What Asian Biotech Firms Must Know About Clinical Trial Efficiency

Clinical Trial Design is crucial for success in pharma; FDA's new rules could ease burdens but raise quality standards.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.